Meeting
2020 ASCO Virtual Scientific Program
Comparison of genomic instability test scores used for predicting PARP activity in ovarian cancer.
Authors
Kirsten M Timms
Myriad Genetic Laboratories, Inc., Salt Lake City, UT
Kirsten M Timms , Gordon B. Mills , Michael Perry , Alexander Gutin , Jerry Lanchbury , Robert Brown
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Cancer Prevention, Risk Reduction, and Genetics
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Germline Genetic Testing
Citation
J Clin Oncol 38: 2020 (suppl; abstr 1586)
DOI
10.1200/JCO.2020.38.15_suppl.1586
Abstract #
1586
Poster Bd #
78
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Detection of homologous recombination deficiency (HRD) in cell-free DNA (cfDNA) using an amplicon-based next-generation sequencing (NGS) assay.
First Author: Jonathan Poh
Poster
2023 ASCO Annual Meeting
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
First Author: Muhammad Danyal Ahsan
Poster
2020 Gastrointestinal Cancers Symposium
Homologous recombination deficiency (HRD) by BROCA-HR and survival outcomes after surgery for patients (pts) with pancreatic adenocarcinoma (PC): A single institution experience.
First Author: Amy E. Chang
Poster
2023 ASCO Annual Meeting
A four-tier classification system for studying homologous recombination repair gene reversion mutations as a mechanism of resistance to PARP inhibitors and platinum chemotherapy.
First Author: Qiuxiang Ou